NYSE:GSKGlaxoSmithKline Stock Price, Forecast & News

$40.89

-0.14 (-0.34 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$40.49

Now: $40.89▼

$41.09

50-Day Range

$37.14

MA: $40.94▼

$42.74

52-Week Range

$31.43

Now: $40.89▼

$48.25

Volume1.62 million shs

Average Volume3.45 million shs

Market Capitalization$102.57 billion

P/E Ratio14.92

Dividend Yield4.54%

Beta0.73

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Beat the Market (BTM) Rank^™

2.1 Analyst's Opinion

Consensus Rating
GlaxoSmithKline has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 5 buy ratings, 3 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.00, GlaxoSmithKline has a potential upside of 10.1% from its current price of $40.89.
Amount of Analyst Coverage
GlaxoSmithKline has only been the subject of 3 research reports in the past 90 days.

2.0 Community Rank

Outperform Votes
GlaxoSmithKline has received 752 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GlaxoSmithKline has received 1,103 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
GlaxoSmithKline has received 59.46% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote “Outperform” if you believe GSK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
GlaxoSmithKline is a leading dividend payer. It pays a dividend yield of 4.54%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
GlaxoSmithKline has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of GlaxoSmithKline is 58.68 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 63.27 % next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlaxoSmithKline insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 10.00% of the stock of GlaxoSmithKline is held by insiders.
Percentage Held by Institutions
Only 12.42% of the stock of GlaxoSmithKline is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for GlaxoSmithKline are expected to grow by 0.68% in the coming year, from $2.92 to $2.94 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlaxoSmithKline is 14.92, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.80.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlaxoSmithKline is 14.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.
Price to Earnings Growth Ratio
GlaxoSmithKline has a PEG Ratio of 6.49. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
GlaxoSmithKline has a P/B Ratio of 4.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.73 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:GSK

Previous Symbol

CUSIPN/A

CIK1131399

Webwww.gsk.com

Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio1.23

Current Ratio0.87

Quick Ratio0.63

Price-To-Earnings

Trailing P/E Ratio14.92

Forward P/E Ratio14.00

P/E Growth6.49

Sales & Book Value

Annual Sales$43.10 billion

Price / Sales2.38

Cash Flow$4.33 per share

Price / Cash Flow9.44

Book Value$9.40 per share

Price / Book4.35

Profitability

EPS (Most Recent Fiscal Year)$3.17

Net Income$5.93 billion

Net Margins15.28%

Return on Equity43.97%

Return on Assets8.39%

Miscellaneous

Employees99,437

Outstanding Shares2,508,520,000

Market Cap$102.57 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

How has GlaxoSmithKline's stock been impacted by COVID-19 (Coronavirus)?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GSK shares have increased by 2.6% and is now trading at $40.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GlaxoSmithKline?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 3 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GlaxoSmithKline.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for GlaxoSmithKline.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings data on Wednesday, October, 30th. The pharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.10. The pharmaceutical company had revenue of $11.57 billion for the quarter, compared to analysts' expectations of $11.34 billion. GlaxoSmithKline had a net margin of 15.28% and a return on equity of 43.97%. View GlaxoSmithKline's earnings history.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, April 30th. Investors of record on Friday, May 15th will be given a dividend of $0.472 per share on Thursday, July 9th. This represents a $1.89 annualized dividend and a dividend yield of 4.62%. The ex-dividend date of this dividend is Thursday, May 14th. View GlaxoSmithKline's dividend history.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline updated its FY20 earnings guidance on Wednesday, April, 29th. The company provided earnings per share guidance of $1.19-1.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.15.

What price target have analysts set for GSK?

11 analysts have issued 12-month price targets for GlaxoSmithKline's shares. Their forecasts range from $45.00 to $45.00. On average, they expect GlaxoSmithKline's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 10.1% from the stock's current price. View analysts' price targets for GlaxoSmithKline.

Has GlaxoSmithKline been receiving favorable news coverage?

News headlines about GSK stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutGlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Sanofi (SNY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Johnson & Johnson (JNJ), Cisco Systems (CSCO), AbbVie (ABBV), Gilead Sciences (GILD), Walt Disney (DIS), Intel (INTC) and NVIDIA (NVDA).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:

Ms. Emma N. Walmsley, CEO & Director (Age 49)
Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
Mr. Jack Bailey, Pres of US Pharmaceuticals
Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.62%), Capital International Investors (0.59%), State Street Corp (0.36%), Morgan Stanley (0.18%), Nuveen Asset Management LLC (0.17%) and Rockefeller Capital Management L.P. (0.15%). View institutional ownership trends for GlaxoSmithKline.

Which major investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Federated Hermes Inc., Eaton Vance Management, Bank of New York Mellon Corp, BlackRock Inc., Voloridge Investment Management LLC, 1832 Asset Management L.P., and Euro Pacific Asset Management LLC. View insider buying and selling activity for GlaxoSmithKline.

Which major investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Rockefeller Capital Management L.P., Camber Capital Management LP, Morgan Stanley, Nuveen Asset Management LLC, Advisor Group Holdings Inc., Connor Clark & Lunn Investment Management Ltd., and Two Sigma Investments LP. View insider buying and selling activity for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $40.89.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $102.57 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis. GlaxoSmithKline employs 99,437 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff